Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on the development of first-in-class nanocatalysts for the treatment of bioenergetic failure associated with neurodegenerative diseases, today announced the $42.5 million oversubscribed closing of its Series D equity financing. Proceeds from the financing will be used to advance Clene’s clinical pipeline—particularly the lead nanocatalyst, CNM-Au8—an orally administered therapeutic under investigation for the neurorepair of various neurodegenerative diseases including multiple sclerosis, Parkinson’s disease, and ALS, with one Phase 3 trial and four Phase 2 studies ongoing.